133 related articles for article (PubMed ID: 34297567)
21. Effective degradation of EGFR
Qu X; Liu H; Song X; Sun N; Zhong H; Qiu X; Yang X; Jiang B
Eur J Med Chem; 2021 Jun; 218():113328. PubMed ID: 33773286
[TBL] [Abstract][Full Text] [Related]
22. Human defensin-inspired discovery of peptidomimetic antibiotics.
Luo G; Zhang J; Wang H; Sun Y; Cheng B; Xu Z; Zhang Y; Li H; Lu W; Nemeth E; Ganz T; Fang X
Proc Natl Acad Sci U S A; 2022 Mar; 119(10):e2117283119. PubMed ID: 35238683
[TBL] [Abstract][Full Text] [Related]
23. Design of peptidomimetics for inhibition of HER2 receptor dimerization by a combination of virtual screening, MD simulations, and QSAR in silico methods.
Jamalan M; Zeinali M; Barzegari Asadabadi E
Chem Biol Drug Des; 2013 Apr; 81(4):455-62. PubMed ID: 23006820
[TBL] [Abstract][Full Text] [Related]
24. Cyclic RGD peptidomimetics containing 4- and 5-amino-cyclopropane pipecolic acid (CPA) templates as dual αVβ3 and α5β1 integrin ligands.
Sernissi L; Trabocchi A; Scarpi D; Bianchini F; Occhiato EG
Bioorg Med Chem; 2016 Feb; 24(4):703-11. PubMed ID: 26753814
[TBL] [Abstract][Full Text] [Related]
25. Discovery of a new isomannide-based peptidomimetic synthetized by Ugi multicomponent reaction as human tissue kallikrein 1 inhibitor.
Barros TG; Santos JAN; de Souza BEG; Sodero ACR; de Souza AMT; da Silva DP; Rodrigues CR; Pinheiro S; Dias LRS; Abrahim-Vieira B; Puzer L; Muri EMF
Bioorg Med Chem Lett; 2017 Jan; 27(2):314-318. PubMed ID: 27914800
[TBL] [Abstract][Full Text] [Related]
26. Identification of constrained peptidomimetic chemotypes as HIV protease inhibitors.
Calugi C; Guarna A; Trabocchi A
Eur J Med Chem; 2014 Sep; 84():444-53. PubMed ID: 25042102
[TBL] [Abstract][Full Text] [Related]
27. A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor.
Emanuel SL; Engle LJ; Chao G; Zhu RR; Cao C; Lin Z; Yamniuk AP; Hosbach J; Brown J; Fitzpatrick E; Gokemeijer J; Morin P; Morse BA; Carvajal IM; Fabrizio D; Wright MC; Das Gupta R; Gosselin M; Cataldo D; Ryseck RP; Doyle ML; Wong TW; Camphausen RT; Cload ST; Marsh HN; Gottardis MM; Furfine ES
MAbs; 2011; 3(1):38-48. PubMed ID: 21099371
[TBL] [Abstract][Full Text] [Related]
28. Laser capture microdissection and protein microarray analysis of human non-small cell lung cancer: differential epidermal growth factor receptor (EGPR) phosphorylation events associated with mutated EGFR compared with wild type.
VanMeter AJ; Rodriguez AS; Bowman ED; Jen J; Harris CC; Deng J; Calvert VS; Silvestri A; Fredolini C; Chandhoke V; Petricoin EF; Liotta LA; Espina V
Mol Cell Proteomics; 2008 Oct; 7(10):1902-24. PubMed ID: 18687633
[TBL] [Abstract][Full Text] [Related]
29. EBP50 inhibits EGF-induced breast cancer cell proliferation by blocking EGFR phosphorylation.
Yao W; Feng D; Bian W; Yang L; Li Y; Yang Z; Xiong Y; Zheng J; Zhai R; He J
Amino Acids; 2012 Nov; 43(5):2027-35. PubMed ID: 22476347
[TBL] [Abstract][Full Text] [Related]
30. Computational Evaluation and In Vitro Validation of New Epidermal Growth Factor Receptor Inhibitors.
Gómez-Ganau S; Castillo J; Cervantes A; de Julián-Ortiz JV; Gozalbes R
Curr Top Med Chem; 2020; 20(18):1628-1639. PubMed ID: 32493189
[TBL] [Abstract][Full Text] [Related]
31. Discovery of Peptidomimetic Ligands of EED as Allosteric Inhibitors of PRC2.
Barnash KD; The J; Norris-Drouin JL; Cholensky SH; Worley BM; Li F; Stuckey JI; Brown PJ; Vedadi M; Arrowsmith CH; Frye SV; James LI
ACS Comb Sci; 2017 Mar; 19(3):161-172. PubMed ID: 28165227
[TBL] [Abstract][Full Text] [Related]
32. Three-dimensional lung tumor microenvironment modulates therapeutic compound responsiveness in vitro--implication for drug development.
Ekert JE; Johnson K; Strake B; Pardinas J; Jarantow S; Perkinson R; Colter DC
PLoS One; 2014; 9(3):e92248. PubMed ID: 24638075
[TBL] [Abstract][Full Text] [Related]
33. A low-molecular-weight compound exerts anticancer activity against breast and lung cancers by disrupting EGFR/Eps8 complex formation.
Li M; Yang J; Zhang L; Tu S; Zhou X; Tan Z; Zhou W; He Y; Li Y
J Exp Clin Cancer Res; 2019 May; 38(1):211. PubMed ID: 31118055
[TBL] [Abstract][Full Text] [Related]
34. Discovery of a d-pro-lys peptidomimetic inhibitor of MMP9: Addressing the gelatinase selectivity beyond S1' subsite.
Lenci E; Contini A; Trabocchi A
Bioorg Med Chem Lett; 2020 Oct; 30(20):127467. PubMed ID: 32768649
[TBL] [Abstract][Full Text] [Related]
35. Small Scorpion-like Peptidomimetics: Potential Broad-Spectrum Membrane Active Antimicrobials without Detectable Resistance.
Zhang E; Qin S
J Med Chem; 2021 Jul; 64(14):9891-9893. PubMed ID: 34197106
[TBL] [Abstract][Full Text] [Related]
36. A novel peptidomimetic therapeutic for selective suppression of lung cancer stem cells over non-stem cancer cells.
Shukla SP; Raymond A; Rustagi V; Kedika SR; Tran O; Wang L; Guo B; Udugamasooriya DG
Bioorg Chem; 2021 Nov; 116():105340. PubMed ID: 34530236
[TBL] [Abstract][Full Text] [Related]
37. Epidermal growth factor (EGF)-like repeats of human tenascin-C as ligands for EGF receptor.
Swindle CS; Tran KT; Johnson TD; Banerjee P; Mayes AM; Griffith L; Wells A
J Cell Biol; 2001 Jul; 154(2):459-68. PubMed ID: 11470832
[TBL] [Abstract][Full Text] [Related]
38. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
39. Ligand binding effects on the activation of the EGFR extracellular domain.
Shao Q; Zhu W
Phys Chem Chem Phys; 2019 Apr; 21(15):8141-8151. PubMed ID: 30933195
[TBL] [Abstract][Full Text] [Related]
40. Discovery of Potent and Selective Epidermal Growth Factor Receptor (EGFR) Bifunctional Small-Molecule Degraders.
Cheng M; Yu X; Lu K; Xie L; Wang L; Meng F; Han X; Chen X; Liu J; Xiong Y; Jin J
J Med Chem; 2020 Feb; 63(3):1216-1232. PubMed ID: 31895569
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
